This is the protocol for a review and there is no abstract. The objectives are as follows:
To evaluate the beneficial and harmful effects of lamivudine in preventing reactivation of HBV during or following immunosuppressive therapy in HBsAg-positive patients.
To estimate the optimal time of initiating lamivudine prophylactic therapy in HBsAg-positive patients receiving immunosuppressive therapy.
Therapy may be initiated before immunosuppressive therapy has begun or immediately after infection is detected.